A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
As an early event in the viral life cycle, the entry of enveloped viruses into target cells has received considerable attention. Viral fusion to cellular targets has been studied principally with fusion assays in which cells engineered to express the viral envelope are cultured with the target cells. These assays yield valuable information but do not fully recapitulate all of the variables governing the fusion of actual virions to their cellular targets. The virion membrane and the plasma membrane, for example, differ strikingly in their lipid and protein compositions. Two virion-based fusion assays have been described. One is based on the redistribution of a self-quenching fluorophore, whereas the second depends on photosensitized activation of a hydrophobic probe by a fluorescent lipid loaded into the target membrane. These assays are complex and have not been adapted to study fusion in complex cell populations. We have developed a simple, rapid assay allowing the detection of HIV-1 virion fusion to biologically relevant target cells, including primary CD4(+) T lymphocytes. It is based on the incorporation of beta-lactamase-Vpr chimeric proteins (BlaM-Vpr) into HIV-1 virions and their subsequent delivery into the cytoplasm of target cells as a result of virion fusion. This transfer is then detected by enzymatic cleavage of the CCF2 dye, a fluorescent substrate of beta-lactamase (BlaM), loaded in the target cells. BlaM cleaves the beta-lactam ring in CCF2, changing its fluor…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Nguyen, D. H., & Hildreth, J. E. K. (2000) · Journal of Virology · doi:10.1128/jvi.74.7.3264-3272.2000 · Cited by 788
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5698 · Cited by 751 · cited 1×
“Conversely, no shift to increased blue fluorescence was observed in these CCR5-Jurkat T cells when the culture was preincubated with 250 nM TAK-779, an inhibitor of CCR5-dependent entr”
BackgroundZlokarnik, G., Negulescu, P. A., Knapp, T. E., Mere, L., Burres, N., Feng, L., Whitney, M., Roemer, K., & Tsien, R. Y. (1998) · Science · doi:10.1126/science.279.5347.84 · Cited by 690
Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4
Schols, D., Struyf, S., Damme, J. V., Esté, J. A., Henson, G., & Clercq, E. D. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.8.1383 · Cited by 554 · cited 1×
“Consistent with this color change deriving from the fusion of virions to the target cells, essentially no blue cells were detected in virally infected HeLa-CD4 cells pretreated with 250 nM AMD3100, an inhibitor of CXCR4-dependent viral entr”
BackgroundAloia, R. C., Tian, H., & Jensen, F. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.11.5181 · Cited by 440
Nussbaum, O., Broder, C. C., & Berger, E. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5411-5422.1994 · Cited by 338
Dynamic Disruptions in Nuclear Envelope Architecture and Integrity Induced by HIV-1 Vpr
de Noronha, C. M. C., Sherman, M. P., Lin, H. W., Cavrois, M. V., Moir, R. D., Goldman, R. D., & Greene, W. C. (2001) · Science · doi:10.1126/science.1063957 · Cited by 276 · cited 1×
“1-BlaM into the Hin dIII site of pCMV4-HA-Vpr (ref”
MethodSelf-citationHIV-1 Actively Replicates in Naive CD4+ T Cells Residing within Human Lymphoid Tissues
Eckstein, D. A., Penn, M. L., Korin, Y. D., Scripture-Adams, D. D., Zack, J. A., Kreisberg, J. F., Roederer, M., Sherman, M. P., Chin, P. S., & Goldsmith, M. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00217-5 · Cited by 232
Bridger, G. J., Skerlj, R. T., Thornton, D., Padmanabhan, S., Martellucci, S. A., Henson, G. W., Abrams, M. J., Yamamoto, N., & Vreese, K. D. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00002a019 · Cited by 209
Cytosolic Gag p24 as an Index of Productive Entry of Human Immunodeficiency Virus Type 1
Maréchal, V., Clavel, F., Heard, J. M., & Schwartz, O. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2208-2212.1998 · Cited by 207 · cited 1×
“However, in the absence of appropriate viral receptors in the vesicles, this entry pathway does not lead to productive infectio”
Background
Cited by
Items 201–300 of 490
PI4P5-Kinase Iα Is Required for Efficient HIV-1 Entry and Infection of T Cells
Barrero-Villar, M., González, J. B., Cabrero, J. R., Gordón‐Alonso, M., Álvarez, S., Muñoz‐Fernández, M. Á., Sánchez‐Madrid, F., & Valenzuela-Fernández, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6882 · Cited by 49
“To further analyze the role of PI4P5-K I during HIV-1 infection, we have performed viral fusion and entry experiments by using R5- and X4-tropic HIV-1 viral particles containing the BlaM-Vpr chimera (24).”
MethodHIV-1 requires Arf6-mediated membrane dynamics to efficiently enter and infect T lymphocytes
García-Expósito, L., González, J. B., Puigdomènech, I., Machado, J. D., Blanco, J., & Valenzuela-Fernández, A. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-08-0722 · Cited by 44
“…detection of viral entry due to the quantitative measurement of the incorporated BlaM-Vpr chimeric virions present at cytoplasm after viral fusion (Cavrois et al., 2002), avoiding interference with viruses captured in vesicular compartments, which may account for 60–90% of total viral uptake…”
BackgroundInfluentialYamamoto, M., Du, Q., Song, J., Wang, H., Watanabe, A., Tanaka, Y., Kawaguchi, Y., Inoue, J., & Matsuda, Z. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004579 · Cited by 42
“Our approach is similar to the BlaM assay (27).”
ResultThe HIV-1 Viral Protease Is Activated during Assembly and Budding Prior to Particle Release
Tabler, C. O., Wegman, S. J., Chen, J., Shroff, H., Alhusaini, N., & Tilton, J. C. (2022) · Journal of Virology · doi:10.1128/jvi.02198-21 · Cited by 42
“In place of VIPER-Vpr, the HIV-1 core (NL4-3) was cotransfected using PEI in a 3:1 ratio with b-lactamase-Vpr, which cleaves CCF2-AM for analysis of viral fusion in a mechanism that has been previously described (56, 57).”
MethodLabib, M., Martić, S., Shipman, P. O., & Kraatz, H. (2011) · Talanta · doi:10.1016/j.talanta.2011.04.070 · Cited by 40
Łyszkiewicz, M., Ziętara, N., Frey, L., Pannicke, U., Stern, M., Liu, Y., Fan, Y., Puchałka, J., Hollizeck, S., Somekh, I., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14809-9 · Cited by 42
Labib, M., Shipman, P. O., Martić, S., & Kraatz, H. (2010) · The Analyst · doi:10.1039/c0an00741b · Cited by 40
Dragin, L., Nguyen, L. A., Lahouassa, H., Sourisce, A., Kim, B., Ramírez, B. C., & Margottin-Goguet, F. (2013) · Retrovirology · doi:10.1186/1742-4690-10-30 · Cited by 39
CCR5 structural plasticity shapes HIV-1 phenotypic properties
Colin, P., Zhou, Z., Staropoli, I., García‐Pérez, J., Gasser, R., Armani-Tourret, M., Bénureau, Y., Gonzàlez, N., Jin, J., Connell, B. J., et al. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1007432 · Cited by 39
Analysis of CA Content and CPSF6 Dependence of Early HIV-1 Replication Complexes in SupT1-R5 Cells
Zila, V., Müller, T. G., Laketa, V., Müller, B., & Kräusslich, H.-G. (2019) · mBio · doi:10.1128/mbio.02501-19 · Cited by 41
Inhibition of HIV Replication by Apolipoprotein A-I Binding Protein Targeting the Lipid Rafts
Dubrovsky, L., Ward, A. R., Choi, S., Pushkarsky, T., Břicháček, B., Vanpouille, C., Adzhubei, A. A., Mukhamedova, N., Sviridov, D., Margolis, L. B., et al. (2020) · mBio · doi:10.1128/mbio.02956-19 · Cited by 41
“The fluorescence HIV-1 virion-based assay was used as previously described (45).”
Visualization of retrovirus uptake and delivery into acidic endosomes
Miyauchi, K., Marin, M., & Melikyan, G. B. (2011) · Biochemical Journal · doi:10.1042/bj20101588 · Cited by 42
“A fully inhibitory concentration of C52L was added at varied times of virus-cell incubation at 37°C, and the resulting HIV-cell fusion was measured by the β-lactamase assay [29].”
Wang, W., Guo, J., Yu, D., Vorster, P. J., Chen, W., & Wu, Y. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.362400 · Cited by 41
“The Vpr- -lactamase-based entry assay (32) showed a roughly 50% reduction of viral entry in naiveT cells (Fig.”
MethodGarcía‐Pérez, J., Staropoli, I., Azoulay, S., Heinrich, J.-T., Cascajero, A., Colin, P., Lortat‐Jacob, H., Arenzana‐Seisdedos, F., Alcamí, J., Kellenberger, E., et al. (2015) · Retrovirology · doi:10.1186/s12977-015-0177-1 · Cited by 40
Zhang, J.-X., Diehl, G. E., & Littman, D. R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002035 · Cited by 46
“To measure virus entry, we utilized the Vpr-β-lactamase assay”
MethodRabi, S. A., O’Connell, K. A., Nikolaeva, D., Bailey, J. R., Jilek, B. L., Shen, L., Page, K. R., Siliciano, R. F., & Blankson, J. N. (2010) · Journal of Virology · doi:10.1128/jvi.01721-10 · Cited by 41
“patients by using a previously described viral fusion assay (12).”
MethodCobbin, J. C. A., Verity, E. E., Gilbertson, B. P., Rockman, S. P., & Brown, L. E. (2013) · Journal of Virology · doi:10.1128/jvi.02856-12 · Cited by 37
“A -lactamase reporter assay (20) was used to compare the activities of viral polymerase complexes.”
MethodCholesterol in the Viral Membrane is a Molecular Switch Governing HIV‐1 Env Clustering
Nieto‐Garai, J. A., Arboleya, A., Otaegi-Ugartemendia, S., Chojnacki, J., Casas, J., Fabriàs, G., Contreras, F. ‐., Kräusslich, H., & Lorizate, M. (2020) · Advanced Science · doi:10.1002/advs.202003468 · Cited by 37
Targeting Spare CC Chemokine Receptor 5 (CCR5) as a Principle to Inhibit HIV-1 Entry
Jin, J., Colin, P., Staropoli, I., Lima‐Fernandes, E., Ferret, C., Demir, A. M., Rogée, S., Hartley, O., Randriamampita, C., Scott, M. G. H., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.559831 · Cited by 37
“3Ren-based plasmid expressing the envelope glycoprotein gp160 of the HIV-1 R5-tropic strain Bx08 (11) and pCMV-BlaM-vpr encoding -lactamase fused to the viral protein Vpr (25).”
MethodInfluentialVidricaire, G., Gauthier, S., & Tremblay, M. J. (2007) · The Journal of Infectious Diseases · doi:10.1086/515576 · Cited by 37
“It is important to specify that, although HIV-1 is internalized primarily by endocytosis in trophoblasts [22], CCF2-AM is cytoplasmic and does not reach these compartments [34].”
BackgroundSong, C., & Aiken, C. (2007) · Journal of Virology · doi:10.1128/jvi.00620-07 · Cited by 37
“The assay employed utilizes BlaM as a fusion protein with the viral accessory protein Vpr, which is incorporated specifically into HIV-1 particles via an interaction with Gag during particle assembly (14).”
MethodImaging Tetrahymena ribozyme splicing activity in single live mammalian cells
Hasegawa, S., Jackson, W. C., Tsien, R. Y., & Rao, J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2036553100 · Cited by 37
Flow virometry analysis of envelope glycoprotein conformations on individual HIV virions
Arakelyan, A., Fitzgerald, W., King, D. F. L., Rogers, P., Cheeseman, H. M., Grivel, J., Shattock, R. J., & Margolis, L. B. (2017) · Scientific Reports · doi:10.1038/s41598-017-00935-w · Cited by 37
Monel, B., McKeon, A., Lamothe, P. A., Jani, P., Boucau, J., Pacheco, Y., Jones, R. B., Gall, S. L., & Walker, B. D. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.016 · Cited by 41
“De novo HIV protein production was detected by means of HIV long terminal repeat (LTR)-driven GFP expression (Cavrois et al., 2002; Tilton et al., 2014).”
MethodTargeting CCR5 trafficking to inhibit HIV-1 infection
Boncompain, G., Herit, F., Tessier, S., Lescure, A., Nery, E. D., Gestraud, P., Staropoli, I., Fukata, Y., Fukata, M., Brelot, A., et al. (2019) · Science Advances · doi:10.1126/sciadv.aax0821 · Cited by 38
“(B) Principles of the HIV-1 entry test used (22).”
BackgroundMethodInfluentialA Bioluminogenic Substrate for In Vivo Imaging of β‐Lactamase Activity
Yao, H., So, M., & Rao, J. (2007) · Angewandte Chemie · doi:10.1002/ange.200701931 · Cited by 36
The C-Terminal Sequence of IFITM1 Regulates Its Anti-HIV-1 Activity
Jia, R., Ding, S., Pan, Q., Liu, S., Qiao, W., & Liang, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118794 · Cited by 36
“The experiments were performed as described in [41].”
MethodBeaumont, T., Quakkelaar, E. D., van Nuenen, A. C., Pantophlet, R. A., & Schuitemaker, H. (2004) · Journal of Virology · doi:10.1128/jvi.78.11.5651-5657.2004 · Cited by 43
“However, one way to avoid the possibility of introducing a phenotypically mixed viral quasispecies when determining the neutralization sensitivity of primary virus isolates would be the use of single-round neutralization assays with envelope sequences that have been cloned directly from the primary viruses (4, 10, 11,…”
BackgroundThe A-rich RNA sequences of HIV-1 pol are important for the synthesis of viral cDNA
Keating, C. P., Hill, M. K., Hawkes, D. J., Smyth, R. P., Isel, C., Le, S.-Y., Palmenberg, A. C., Marshall, J. A., Marquet, R., Nabel, G. J., et al. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkn1015 · Cited by 35
“Upon successful virus entry, CCF2 was cleaved by the virion-associated BlaM enzyme, which resulted in a change of its fluorescence emission spectrum from green (520 nm) to blue (447 nm) (52).”
BackgroundMethodXu, Y., Phetsouphanh, C., Suzuki, K., Aggrawal, A., Graff‐Dubois, S., Roche, M., Bailey, M., Alcântara, S., Cashin, K., Sivasubramaniam, R., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00376 · Cited by 37
“pBlaM-vpr were cotransfected into 293 T cells to make CXCR4- or CCR5-using HIV-BlaM as previously described (34).”
MethodInfluentialPhosphorylation of the HIV-1 capsid by MELK triggers uncoating to promote viral cDNA synthesis
Takeuchi, H., Saito, H., Noda, T., Miyamoto, T., Yoshinaga, T., Terahara, K., Ishii, H., Tsunetsugu‐Yokota, Y., & Yamaoka, S. (2017) · PLoS Pathogens · doi:10.1371/journal.ppat.1006441 · Cited by 36
USP18 (UBP43) Abrogates p21-Mediated Inhibition of HIV-1
Kuffour, E. O., Schott, K., Vasudevan, A. A. J., Holler, J. M., Schulz, W. A., Lang, P. A., Lang, K. S., Kim, B., Häussinger, D., König, R., et al. (2018) · Journal of Virology · doi:10.1128/jvi.00592-18 · Cited by 37
“To rule out a block at the membrane fusion step, we tested the HIV-1 VSV-G pseudotype fusion using a virionbased fusion assay as described previously (59, 60).”
MethodJanas, A. M., Dong, C., Wang, J.-H., & Wu, L. J. (2008) · Virology · doi:10.1016/j.virol.2008.01.044 · Cited by 36
“The assay is based on the delivery of beta-lactamase (BlaM)-Vprincorporated HIV-1 into the cytoplasm of target cells upon virion fusion (Cavrois et al., 2002).”
BackgroundMethodInfluentialIP-10 Promotes Latent HIV Infection in Resting Memory CD4+ T Cells via LIMK-Cofilin Pathway
Wang, Z., Yin, X., Ma, M., Ge, H., Lang, B., Sun, H., He, S., Fu, Y., Sun, Y., Yu, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656663 · Cited by 34
“entry using the BlaM-Vpr entry assay (43), and found that IP-10 pretreatment of resting memory CD4 T cells increased viral entry (NL4-3+IP-10 vs NL4-3; P=0.”
BackgroundMethodRepurposing of berbamine hydrochloride to inhibit Ebola virus by targeting viral glycoprotein
Cen, S., Li, Q., Li, Q., Qiu, X., Wang, H., Liu, Z., He, S., Zhu, W., Lv, K. L., Li, X., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.023 · Cited by 34
“We next tested whether the fusion of viral and cellular 113 membranes is inhibited by EEI-10 using a beta-lactamase-Vpr chimeric protein (BlaM-Vpr) release assay that 114 has been established to measure the delivery of HIV-1 core into the cytoplasm(29).”
MethodBrandano, L., & Stevenson, M. (2012) · Journal of Virology · doi:10.1128/jvi.06047-11 · Cited by 30
“We used a recently modified fusion assay that measures BLaM activity as an indicator of virus-cell fusion events in living TZM-bl cells postfusion with virus containing chimeric BLaM-Vpr proteins (9, 38).”
MethodHIV‐1 Interactions with Cells: From Viral Binding to Cell‐Cell Transmission
Janas, A. M., & Wu, L. J. (2009) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb2605s43 · Cited by 43
“A sensitive and specific enzyme-based assay has been reported to detect HIV-1 virion fusion in primary T lymphocytes (Cavrois et al., 2002).”
MethodOzog, S., Timberlake, N. D., Hermann, K. J., Garijo, O., Haworth, K. G., Shi, G., Glinkerman, C. M., Schefter, L. E., D'Souza, S. S., Simpson, E., et al. (2019) · Blood · doi:10.1182/blood.2019000040 · Cited by 33
Singh, P., Mukherji, S., Basak, S., Hoffmann, M., & Das, D. K. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110694 · Cited by 34
“To understand the calcium concentration sensitivity in conformational change, we performed FRET Cell Reports 39, 110694, April 19, 2022 9 (A) Fluorescence resonance energy transfer (FRET) assay design for probing spike (S) protein conformation change from pre-fusion to post-fusion state by incubating pseudovirions hav…”
InfluentialGoffinet, C., Michel, N., Allespach, I., Tervo, H.-M., Hermann, V., Kräusslich, H., Greene, W. C., & Keppler, O. T. (2007) · Retrovirology · doi:10.1186/1742-4690-4-53 · Cited by 39
“To directly compare the efficiencies of R5 HIV-1 entry in T-cells from hCD4/hCCR5-transgenic rats and human reference cultures, we employed a sensitive and specific virion-fusion assay [22,24,25].”
MethodInfluentialSelf-citationATPγS Disrupts Human Immunodeficiency Virus Type 1 Virion Core Integrity
Gurer, C., Höglund, A., Höglund, S., & Luban, J. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5557-5567.2005 · Cited by 36
“described previously (19) with the GeneBLAzer in vivo detection kit (Invitro-”
MethodLentivirus-Based Virus-Like Particles as a New Protein Delivery Tool
Muratori, C., Bona, R., & Federico, M. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-533-0_7 · Cited by 32
Santos, C. D. S., Tartour, K., & Cimarelli, A. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005897 · Cited by 32
HIV infection is influenced by dynamin at 3 independent points in the viral life cycle
Aggarwal, A., Hitchen, T. L., Ootes, L., McAllery, S., Wong, A. K. H., Nguyen, K., McCluskey, A., Robinson, P. J., & Turville, S. G. (2017) · Traffic · doi:10.1111/tra.12481 · Cited by 32
“The kinetics of HIV entry into the cytoplasm of CD4 T cells was determined using a Vpr-BlaM fusion assay.(84) Briefly, cells (1 × 10(6) for resting and activated CD4 T cells or 3 × 10(4) for TZM-bl and TZM-bl-Lck cells) were treated with vehicle DMSO, dyngo-4a (80 μM), ryngo-1-23 (80 μM), AMD3100 (10 μM), BMS-378806 (…”
MethodHigh-Throughput HIV–Cell Fusion Assay for Discovery of Virus Entry Inhibitors
Marin, M., Du, Y., Giroud, C., Kim, J. H., Qui, M., Fu, H., & Melikyan, G. B. (2015) · Assay and Drug Development Technologies · doi:10.1089/adt.2015.639 · Cited by 33
“HIV-1 fusion with target cells was measured using the BlaM assay, 42,43 which measures the activity of b -lactamase incorporated into virions using the b -lactamase Vpr chimera.”
Wolf, M. C., Wang, Y., Freiberg, A. N., Aguilar, H. C., Holbrook, M. R., & Lee, B. (2009) · Virology Journal · doi:10.1186/1743-422x-6-119 · Cited by 32
“For example, entry assays using vpr-βla for HIV and βla-matrix for Ebola have been described[48,49], yet the published assays would appear to be less sensitive than our current system[48,50].”
MethodThe β-Lactamase Assay: Harnessing a FRET Biosensor to Analyse Viral Fusion Mechanisms
Jones, D. M., & Padilla‐Parra, S. (2016) · Sensors · doi:10.3390/s16070950 · Cited by 36
“Another potential reason concerns the instrument used to collect the data; the fact that the BlaM assay produces fluorescence-based readout means that measurements can be acquired through a variety of means including microscopy [15,19,23,35], flow cytometry [4,17,22,24,26,38] or plate reader-based analyses [11,12,14,1…”
BackgroundMethodInfluentialRole of HIV-2 envelope in Lv2-mediated restriction
Reuter, S., Kaumanns, P., Buschhorn, S. B., & Dittmar, M. T. (2004) · Virology · doi:10.1016/j.virol.2004.11.025 · Cited by 32
“This assay has been shown to discriminate between fusion and endocytosis of virions due to the lack of CCF2/ AM availability within endosomes (Cavrois et al., 2002; Schaeffer et al., 2004).”
MethodJiang, J., & Aiken, C. (2005) · Virology · doi:10.1016/j.virol.2005.11.008 · Cited by 32
“The virion-based fusion assay was performed as described previously (Cavrois et al., 2002; Wyma et al., 2004).”
BackgroundMethodRodriguez-Plata, M. T., Urrutia, A., Cardinaud, S., Buzón, M. J., Izquierdo‐Useros, N., Prado, J. G., Puertas, M. C., Erkizia, I., Coulon, P.-G. A., Cedeño, S., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200267 · Cited by 33
HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells
Chauveau, L., Puigdomènech, I., Ayinde, D., Roesch, F., Porrot, F., Bruni, D., Visseaux, B., Descamps, D., & Schwartz, O. (2015) · Retrovirology · doi:10.1186/s12977-014-0131-7 · Cited by 31
Yegorov, S., Joag, V., Galiwango, R. M., Good, S. V., Mpendo, J., Tannich, E., Boggild, A. K., Kiwanuka, N., Bagaya, B. S., & Kaul, R. (2019) · Nature Communications · doi:10.1038/s41467-019-09900-9 · Cited by 32
Barnard, R. J. O., Narayan, S., Dornadula, G., Miller, M. D., & Young, J. A. T. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10433-10441.2004 · Cited by 36
“In order to explore whether low pH could be required to initiate events subsequent to ASLV Env-driven fusion, we used an assay that monitors penetration into the cytosol by pHindependent HIV-1 viral cores that contain a Vpr-BlaM fusion protein ( 5 , 32, 43).”
MethodN-terminal Slit2 inhibits HIV-1 replication by regulating the actin cytoskeleton
Anand, A. R., Zhao, H., Tirumuru, N., Robinson, L. A., & Ganju, R. K. (2013) · Retrovirology · doi:10.1186/1742-4690-10-2 · Cited by 32
Chen, D., Hou, Z., Jiang, D., Zheng, M., Li, G., Zhang, Y., Li, R., Lin, H., Chang, J., Zeng, H., et al. (2019) · Emerging Microbes & Infections · doi:10.1080/22221751.2019.1677446 · Cited by 31
“The Blam-Vpr based entry assay was applied to study the e ff ect of IFN-γ on viral entry as described previously [36].”
Site-specific Gene Insertion Mediated by a Cre-loxP-carrying Lentiviral Vector
Michel, G., Yu, Y., Chang, T., & Yee, J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.150 · Cited by 33
Cavrois, M., Neidleman, J. A., & Greene, W. C. (2014) · BIO-PROTOCOL · doi:10.21769/bioprotoc.1212 · Cited by 30
“Development media 2.5 mM probenecid 10% fetal bovine serum in CO2-independent media Acknowledgments This assay was first published in (Cavrois et al., 2002) and the protocol described in detail in (Cavrois et al., 2004).”
MethodSelf-citationProtein transduction by pseudotyped lentivirus-like nanoparticles
Aoki, T., Miyauchi, K., Urano, E., Ichikawa, R., & Komano, J. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.38 · Cited by 31
Novel, rapid assay for measuring entry of diverse enveloped viruses, including HIV and rabies
Saeed, M. F., Kolokoltsov, A. A., & Davey, R. A. (2006) · Journal of Virological Methods · doi:10.1016/j.jviromet.2006.02.011 · Cited by 30
Kolokoltsov, A. A., & Davey, R. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5124-5132.2004 · Cited by 33
“Both GFP and -lactamase fused to the HIV Vpr protein can be incorporated at low levels (5, 18).”
BackgroundMethodInfluentialCharacterization of Endogenous SERINC5 Protein as Anti-HIV-1 Factor
Passos, V., Zillinger, T., Casartelli, N., Wachs, A. S., Xu, S., Malassa, A., Steppich, K., Schilling, H., Franz, S., Tödt, D., et al. (2019) · Journal of Virology · doi:10.1128/jvi.01221-19 · Cited by 29
“3 nef proviral DNA, 3 g BlaM-Vpr DNA, and 1 g pAdvantage (30).”
BackgroundPutcharoen, O., Lee, S. H., Henrich, T. J., Hu, Z., Vanichanan, J., Coakley, E. P. G., Greaves, W. L., Gulick, R. M., Kuritzkes, D. R., & Tsibris, A. M. N. (2011) · Journal of Virology · doi:10.1128/jvi.06421-11 · Cited by 29
“assay to quantify virus-cell fusion in real time and investigate the effects of CCR5 antagonist resistance on entry kinetics (4, 29).”
MethodIntercellular Adhesion Molecule 1 Promotes HIV-1 Attachment but Not Fusion to Target Cells
Kondo, N., & Melikyan, G. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044827 · Cited by 31
“The ICAM-1 effect on HIV-1 fusion was next evaluated, using the b-lactamase (BlaM) assay which measures transfer of the viral core-associated enzyme into the cytoplasm [52].”
MethodUchil, P. D., & Mothes, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.033 · Cited by 35
“In the cytosol, this enzyme shifts the emission wavelength of a fluorescent reagent, making content mixing easy to measure (Cavrois et al., 2002).”
BackgroundRuedas, J. B., Ladner, J. T., Ettinger, C. R., Gummuluru, S., Palacios, G. F., & Connor, J. H. (2017) · Journal of Virology · doi:10.1128/jvi.00392-17 · Cited by 29
“Lentivirus virus-like particles (VLPs) were created using a beta-lactamase (BlaM)-Vpr fusion protein that is incorporated in VLPs (12).”
MethodInfluentialDual Split Protein (DSP) Assay to Monitor Cell–Cell Membrane Fusion
Nakane, S., & Matsuda, Z. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2703-6_17 · Cited by 29
Nonhuman Primate IFITM Proteins Are Potent Inhibitors of HIV and SIV
Wilkins, J. M., Zheng, Y.-M., Yu, J., Liang, C., & Liu, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0156739 · Cited by 31
“The fusion assay was performed as previously described [43].”
InfluentialPlasmonic Enhancement of Selective Photonic Virus Inactivation
Nazari, M., Xi, M., Lerch, S., Alizadeh, M. H., Ettinger, C. R., Akiyama, H., Gillespie, C. M., Gummuluru, S., Erramilli, S., & Reinhard, B. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-12377-5 · Cited by 28
The late endosome-resident lipid bis(monoacylglycero)phosphate is a cofactor for Lassa virus fusion
Markosyan, R. M., Marin, M., Zhang, Y., Cohen, F. S., & Melikyan, G. B. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009488 · Cited by 28
“In contrast to the effect of BMP on cell-cell fusion, a direct LASV pseudovirus-cell fusion assay based on a beta-lactamase reporter [72] did not reveal a significant effect of this or other lipids Fig 6.”
ResultEfficient delivery of lentiviral vectors into resting human CD4 T cells
Geng, X., Doitsh, G., Yang, Z., Galloway, N. L. K., & Greene, W. C. (2014) · Gene Therapy · doi:10.1038/gt.2014.5 · Cited by 29
Self-citationPadilla‐Parra, S., Marin, M., Kondo, N., & Melikyan, G. B. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002694 · Cited by 29
Schenkwein, D., Turkki, V., Kärkkäinen, H.-R., Airenne, K. J., & Ylä‐Herttuala, S. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.051 · Cited by 30
“…(Liu et al. , 1997; Holmes-Son and Chow, 2000, 2002; Tan et al. , 2006), marker or reporter proteins (Sato et al. , 1995; Yao et al. , 1999; Cavrois et al. , 2002; McDonald et al. , 2002; Campbell et al. , 2007; Joo and Wang, 2008), and therapeutic proteins (Link et al. , 2006) into HIV-1…”
Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies
Struble, E. B., Rawson, J. M. O., Stantchev, T. S., Scott, D., & Shapiro, M. A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051538 · Cited by 29
Mouse T-cells restrict replication of human immunodeficiency virus at the level of integration
Tervo, H.-M., Goffinet, C., & Keppler, O. T. (2008) · Retrovirology · doi:10.1186/1742-4690-5-58 · Cited by 29
“Through incorporation of enzymatically active β-lactamase-Vpr fusion proteins (BlaM-Vpr) during virus production the efficiency of HIV-1 entry into target cells was specifically measured by CCF2 substrate cleavage in a flow cytometrybased virion-fusion assay [22,23].”
MethodLucera, M. B., Fleissner, Z., Tabler, C. O., Schlatzer, D., Troyer, Z., & Tilton, J. C. (2017) · Retrovirology · doi:10.1186/s12977-017-0328-7 · Cited by 28
“2247 [26] and a β-lactamase-Vpr fusion protein [27, 28].”
BackgroundSood, C., Francis, A. C., Desai, T. M., & Melikyan, G. B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.818088 · Cited by 30
HIV-1-Based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions
Gonelli, C. A., Khoury, G., & Purcell, D. F. J. (2019) · Viruses · doi:10.3390/v11060507 · Cited by 27
“These sites were then used to ligate the fragment into pMM310 (obtained from NIH ARP) [56] after the removal of the insert.”
MethodHIV envelope tail truncation confers resistance to SERINC5 restriction
Haider, T., Snetkov, X., & Jolly, C. L. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2101450118 · Cited by 27
“Therefore, we tested whether EnvCT truncation allowed HIV-1 to evade SERINC5 inhibition of virion fusion using the Blam-Vpr fusion assay (37).”
MethodIngrao, D., Majdoul, S., Seye, A. K., Galy, A. H. M., & Fenard, D. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.090 · Cited by 26
“Such assay could also be used to monitor the level of infection by following the expression of de novo intracellular HIV-1 gag expression after few days (Cavrois et al. , 2002).”
InfluentialRole of Glycosphingolipids in Dendritic Cell-Mediated HIV-1 Trans-infection
Puryear, W. B., & Gummuluru, S. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-4433-6_5 · Cited by 28
“…in an internal compartment (Frank et al. 2002; Garcia et al. 2005; IzquierdoUseros et al. 2009; Wiley and Gummuluru 2006) or is surface associated (Cavrois et al. 2002; Yu et al. 2008) but regardless of the precise location, virus particles are maintained in an infectious form (Geijtenbeek et al.…”
BackgroundCirculating Monocytes Are Not a Major Reservoir of HIV-1 in Elite Suppressors
Spivak, A. M., Salgado, M., Rabi, S. A., O’Connell, K. A., & Blankson, J. N. (2011) · Journal of Virology · doi:10.1128/jvi.05409-11 · Cited by 30
“We made use of a previously described VPR-BlaM entry assay (10) and found that between 3 and 34% of monocytes were susceptible to HIV-1 entry among individuals; however, no difference with regard to viral entry susceptibility was observed between the three patient groups tested (ES patients, viremic patients, and unin…”
MethodImpaired Infectivity of Ritonavir-resistant HIV Is Rescued by Heat Shock Protein 90AB1
Joshi, P., & Stoddart, C. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248021 · Cited by 25
Desai, T. M., Marin, M., Mason, C. S., & Melikyan, G. B. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.783878 · Cited by 27
“Virus-cell fusion was measured using the -lactamase (BlaM) assay that detects the delivery of virus-incorporated BlaM-Vpr chimeric protein into the cytoplasm (50).”
MethodPaskaleva, E. E., Lin, X., Duus, K., McSharry, J. J., Veille, J.-C., Thornber, C., Liu, Y., Lee, D. Y.-W., & Canki, M. (2008) · Virology Journal · doi:10.1186/1743-422x-5-8 · Cited by 26
“Greene [5], and HIV-1 virions containing the BlaM-Vpr chimera were produced as previously described [5] Briefly, 293T cells in 10 cm2 flasks were cotransfected with pNL4-3 proviral DNA (60 μg), pCMV-BlaM-Vpr (20 μg), and pAdVAntage vectors (10 μg) (Invitrogen).”
MethodNakane, S., Iwamoto, A., & Matsuda, Z. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.628610 · Cited by 25
“The AmpR sequence was identical to the -lactamase used in the original BlaM assay (24).”
MethodImaging real-time HIV-1 virion fusion with FRET-based biosensors
Jones, D. M., & Padilla‐Parra, S. (2015) · Scientific Reports · doi:10.1038/srep13449 · Cited by 26
Roesch, F., OhAinle, M., & Emerman, M. (2018) · Retrovirology · doi:10.1186/s12977-018-0409-2 · Cited by 29
“The SIV3 + , SIV3∆vpx and Vpr-β-lactamase plasmids are kind gifts from Olivier Schwartz [10, 11, 27, 50].”
Meissner, E. G., Coffield, V. M., & Su, L. (2005) · Virology · doi:10.1016/j.virol.2005.03.032 · Cited by 25
“After 8–16 h, fluorescence was measured on a fluorometer and relative fusion was determined by taking the ratio of the blue (cleaved) to green (uncleaved) signal after background correction as previously described (Cavrois et al., 2002).”
MethodNrf2 Expression Modifies Influenza A Entry And Replication In Nasal Epithelial Cells
Kesic, M. J., Simmons, S. O., & Jaspers, I. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a2742 · Cited by 25
Marin, M., Kushnareva, Y., Mason, C. S., Chanda, S. K., & Melikyan, G. B. (2019) · Viruses · doi:10.3390/v11020100 · Cited by 24
“CCR5/shRNA cells was examined using the β-lactamase (BlaM) assay that measures the extent of viral fusion based on the cytosolic β-lactamase activity [14,39].”
MethodFingolimod inhibits multiple stages of the HIV-1 life cycle
Resop, R. S., Fromentin, R., Newman, D., Rigsby, H., Dubrovsky, L., Bukrinsky, M., Chomont, N., & Bosque, A. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008679 · Cited by 25
“TCM were cultured for three hours with NL4-3-BLaM to determine viral fusion with the host cell membrane by incubation with beta-lactamase-Vpr chimeric proteins (BLaM-Vpr) substrate and flow cytometry as previously done [40].”
BackgroundMethodLiu, R., Teo, W., Tan, S., Feng, H., Padmanabhan, P., & Xing, B. (2010) · The Analyst · doi:10.1039/b926909f · Cited by 24
Cavrois, M., Neidleman, J. A., Santiago, M. L., Derdeyn, C. A., Hunter, E., & Greene, W. C. (2013) · Journal of Virology · doi:10.1128/jvi.02308-13 · Cited by 27
“We measured the ability of these Envs to mediate fusion to cellular targets in our virion-based fusion assay (28, 29, 31).”
MethodSelf-citationNathan, L., & Daniel, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-14741-9_2 · Cited by 23
Lodge, R., Bellini, N., Laporte, M., Salahuddin, S., Routy, J., Ancuța, P., Costiniuk, C. T., Jenabian, M.-A., & Cohen, É. A. (2020) · mBio · doi:10.1128/mbio.02314-20 · Cited by 23
“Viral fusion was measured using the Blam-Vpr assay (44) as described previously (24).”
MethodInfluentialRamezani, A., Dubrovsky, L., Pushkarsky, T., Sviridov, D., Karandish, S., Raj, D. S., Fitzgerald, M. L., & Bukrinsky, M. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.224485 · Cited by 23
“FRET-based HIV-1 virion fusion assay was performed as previously described (Cavrois et al., 2002).”
MethodHIV Fusion in Dendritic Cells Occurs Mainly at the Surface and Is Limited by Low CD4 Levels
Chauveau, L., Donahue, D. A., Monel, B., Porrot, F., Bruel, T., Richard, L., Casartelli, N., & Schwartz, O. (2017) · Journal of Virology · doi:10.1128/jvi.01248-17 · Cited by 28
“The cells were then shifted to 37°C for 2 h to permit fusion, which was subsequently measured with a Vpr– -lactamase (Vpr-Blam) fusion assay (20, 42).”
MethodPion, M., Arrighi, J.-F., Jiang, J., Lundquist, C. A., Hartley, O., Aiken, C., & Piguet, V. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700518 · Cited by 23
Delos, S. E., La, B., Gilmartin, A. A., & White, J. M. (2010) · Journal of Virology · doi:10.1128/jvi.02583-09 · Cited by 24
“To determine this, we “forced fusion” by pulsing cells bearing prebound HIV-EnvA-pseudotyped virions containing -lactamase–Vpr with medium of a specified pH and then measured the amount of -lactamase–Vpr delivered to the cytosol of the target cells (3).”
MethodImaging Viral Infection by Fluorescence Microscopy: Focus on HIV-1 Early Stage
Mukherjee, S., Boutant, E., Réal, É., Mély, Y., & Anton, H. (2021) · Viruses · doi:10.3390/v13020213 · Cited by 22
“During the fusion, the BlaM-Vpr is released into the host cell cytoplasm, where it cleaves its fluorescent substrate CCF2, loaded into the cell.”
Background
Metadata
- Authors
- Cavrois, M., de Noronha, C., & Greene, W. C.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Greene, Warner C.
- Venue
- Nature Biotechnology
- Published
- 2002-09-30
- Volume
- 20
- Issue
- 11
- Pages
- 1151-1154
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2029379203
- Cited by
- 475
- References
- 16
- Citations by year
- 2026: 13 · 2025: 11 · 2024: 12 · 2023: 9 · 2022: 19 · 2021: 24 · 2020: 22 · 2019: 25 · 2018: 20 · 2017: 31 · 2016: 16 · 2015: 27 · 2014: 28 · 2013: 22 · 2012: 31
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P01 HD40543, P01HD040543)
- Topics
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- HIV-1, viral entry, fluorescent substrate, HIV-1 envelope
- MeSH terms
- Cell Fusion, Humans, Immunoenzyme Techniques, Membrane Fusion, Sensitivity and Specificity, T-Lymphocytes, Tumor Cells, Cultured, Viral Fusion Proteins, Virion, Reproducibility of Results, HIV-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.